Centre For Probe Development And Commercialization
π¨π¦Canada
- Country
- π¨π¦Canada
- Ownership
- -
- Established
- 1955-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.imagingprobes.ca/
Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.
Phase 3
Completed
- Conditions
- Prostate Cancer RecurrentRecurrent Prostate Cancer
- Interventions
- Diagnostic Test: [18F] PSMA-1007 Injection
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-02-07
- Target Recruit Count
- 100
- Registration Number
- NCT04644822
- Locations
- π¨π¦
London Health Sciences Centre, London, Ontario, Canada
π¨π¦University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours
Phase 1
Completed
- Conditions
- Cancer
- Interventions
- Drug: [I-124]-CPD-1028 InjectionBiological: CPD-1061
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2016-10-18
- Target Recruit Count
- 2
- Registration Number
- NCT02134340
- Locations
- π¨π¦
Juravinski Cancer Centre, Hamilton, Ontario, Canada
π¨π¦University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada
π¨π¦Sunnybrook Health Science Centre - Odette Cancer Centre, Toronto, Ontario, Canada
A Single Centre Open Label Comparison of [I-123]-Ortho-Iodohippuric Acid (OIH) With [Tc-99m]-Mercaptoacetyltriglycine (MAG3) for Assessment of Renal Tubular Function
Completed
- Conditions
- Renal Function Impairment
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2014-04-09
- Target Recruit Count
- 6
- Registration Number
- NCT01496391
- Locations
- π¨π¦
St. Joesph's Healthcare Hamilton, Hamilton, Ontario, Canada
Β© Copyright 2025. All Rights Reserved by MedPath